Literature DB >> 18574657

Five-day oral cefditoren pivoxil versus 10-day oral amoxicillin for pediatric group A streptococcal pharyngotonsillitis.

Takao Ozaki1, Naoko Nishimura, Michio Suzuki, Atsushi Narita, Naoko Watanabe, Jaekun Ahn, Norio Koyama, Hajime Ushida, Kazumasa Nakane, Naoko Yasuda, Keiji Funahashi.   

Abstract

We prospectively compared the efficacy of oral cefditoren-pivoxil and conventional oral amoxicillin for pharyngotonsillitis caused by group A streptococcus in children. Either oral cefditoren-pivoxil (3 mg/kg t.i.d. for 5 days) or amoxicillin (10 mg/kg t.i.d. for 10 days) was administered to patients with group A streptococcal pharyngotonsillitis attending the pediatric outpatient clinic of Showa Hospital (Konan, Japan) between January and December 2006. Diagnosis was based on isolation of bacteria from a pharyngeal swab. Culture was always done to confirm eradication, and urinalysis and follow-up were performed at least once weekly for 4 weeks. Among 258 patients, 103 (aged 5.5 +/- 2.3 years) received cefditoren-pivoxil and 155 (aged 5.2 +/- 2.0 years) received amoxicillin. There were no significant between-group differences in age, sex, or symptoms. Eradication was confirmed in 99% (102/103) of the cefditoren-pivoxil group and 100% of the amoxicillin group. Recurrence within 4 weeks occurred in 8 and 15 patients in the cefditoren-pivoxil and amoxicillin groups, respectively, showing no significant difference in the recurrence rate, and all isolates had the same serotypes as before. There were no clinically significant adverse reactions or complications. The 50%/90% minimum inhibitory concentrations (microg/ml) of cefditoren-pivoxil and amoxicillin for the 258 isolates were < or =0.03/< or =0.03 and < or =0.03/0.06, respectively, so all isolates were susceptible to both agents. Because the efficacy for pediatric group A streptococcus pharyngotonsillitis was similar between oral cefditoren-pivoxil for 5 days and amoxicillin for 10 days, the shorter treatment period may make the former regimen preferable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18574657     DOI: 10.1007/s10156-008-0602-7

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  4 in total

1.  Update on the clinical utility and optimal use of cefditoren.

Authors:  José Barberán; Lorenzo Aguilar; María-José Giménez
Journal:  Int J Gen Med       Date:  2012-05-21

Review 2.  Cefditoren in upper and lower community-acquired respiratory tract infections.

Authors:  Francisco Soriano; María-José Giménez; Lorenzo Aguilar
Journal:  Drug Des Devel Ther       Date:  2011-02-09       Impact factor: 4.162

Review 3.  Guidelines for the Antibiotic Use in Adults with Acute Upper Respiratory Tract Infections.

Authors:  Young Kyung Yoon; Chan Soon Park; Jae Wook Kim; Kyurin Hwang; Sei Young Lee; Tae Hoon Kim; Do Yang Park; Hyun Jun Kim; Dong Young Kim; Hyun Jong Lee; Hyun Young Shin; Yong Kyu You; Dong Ah Park; Shin Woo Kim
Journal:  Infect Chemother       Date:  2017-12

4.  Refractory Peritoneal Dialysis Peritonitis Due to Neisseria macacae: A Case Report and Review of the Literature.

Authors:  Takuji Iyama; Shintaro Hamada; Tomoaki Takata; Shotaro Hoi; Satoko Fukuda; Hajime Isomoto
Journal:  Intern Med       Date:  2020-06-09       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.